Oryon Cell treatments is a clinical-stage biotechnology business exploring autologous cell treatments for neurodegenerative illnesses.
Oryon Cell Therapies has raised $21.0M in total funding. The most recent round was Series A. The last funding was announced in March 2026.
Oryon Cell Therapies's investors include Neuro.VC, Byers Capital.
Oryon Cell Therapies is headquartered in Belmont, United States.
Oryon Cell treatments is a clinical-stage biotechnology business exploring autologous cell treatments for neurodegenerative illnesses.
Oryon Cell Therapies is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Oryon Cell Therapies — Funding & Investors." VCBacked, March 23, 2026, https://www.vcbacked.co/company/oryon-cell-therapies. Accessed September 30, 2026.
VCBacked. (2026). Oryon Cell Therapies — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/oryon-cell-therapies
{{cite web |title=Oryon Cell Therapies — Funding & Investors |url=https://www.vcbacked.co/company/oryon-cell-therapies |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated